Immune dysregulation and system pathology in COVID-19
The coronavirus disease 19 (COVID-19) caused by the novel coronavirus known as SARS-CoV-2 has caused a global public health crisis. As of 7 January 2021, 87,640,402 confirmed cases and 1,891,692 mortalities have been reported worldwide. Studies focusing on the epidemiological and clinical characteristics of COVID-19 patients have suggested a dysregulated immune response characterized by lymphopenia and cytokine storm in these patients. The exaggerated immune response induced by the cytokine storm causes septic shock, acute respiratory distress syndrome (ARDS), and/or multiple organs failure, which increases the fatality rate of patients with SARS-CoV-2 infection. Herein, we review the recent research progress on epidemiology, clinical features, and system pathology in COVID-19. Moreover, we summarized the recent therapeutic strategies, which are either approved, under clinical trial, and/or under investigation by the local or global health authorities. We assume that treatments should focus on the use of antiviral drugs in combination with immunomodulators as well as treatment of the underlying comorbidities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Virulence - 12(2021), 1 vom: 31. Dez., Seite 918-936 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jamal, Muhammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 07.04.2021 Date Revised 19.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/21505594.2021.1898790 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32313663X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32313663X | ||
| 003 | DE-627 | ||
| 005 | 20231225183528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21505594.2021.1898790 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM32313663X | ||
| 035 | |a (NLM)33757410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jamal, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune dysregulation and system pathology in COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2021 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The coronavirus disease 19 (COVID-19) caused by the novel coronavirus known as SARS-CoV-2 has caused a global public health crisis. As of 7 January 2021, 87,640,402 confirmed cases and 1,891,692 mortalities have been reported worldwide. Studies focusing on the epidemiological and clinical characteristics of COVID-19 patients have suggested a dysregulated immune response characterized by lymphopenia and cytokine storm in these patients. The exaggerated immune response induced by the cytokine storm causes septic shock, acute respiratory distress syndrome (ARDS), and/or multiple organs failure, which increases the fatality rate of patients with SARS-CoV-2 infection. Herein, we review the recent research progress on epidemiology, clinical features, and system pathology in COVID-19. Moreover, we summarized the recent therapeutic strategies, which are either approved, under clinical trial, and/or under investigation by the local or global health authorities. We assume that treatments should focus on the use of antiviral drugs in combination with immunomodulators as well as treatment of the underlying comorbidities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a ards and multiple organs failure | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a lymphopenia | |
| 650 | 4 | |a pathogenesis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Bangash, Hina Iqbal |e verfasserin |4 aut | |
| 700 | 1 | |a Habiba, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Yufei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jiaxing |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Zimeng |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Zixi |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiuping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virulence |d 2010 |g 12(2021), 1 vom: 31. Dez., Seite 918-936 |w (DE-627)NLM199668515 |x 2150-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:31 |g month:12 |g pages:918-936 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21505594.2021.1898790 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 31 |c 12 |h 918-936 | ||